Most of the early data was in reduction of cancer rates, especially for cervical cancer, in women. Part of this bias was because the HPV vaccine was originally just indicated for girls and young women. But more recently, the vaccine was approved in most areas of the world to be used with boys and young men.
However, a new study is out that gives us more evidence that the vaccine will prevent cancer in men. And that’s more good news if you’re looking for an effective way to prevent some cancers.
Many of us who provide scientific information about HPV quadrivalent vaccine, also known as Gardasil (or Silgard in Europe), tend to focus on its effects on preventing cancers in women, so articles are inclined to pay attention to vaccinating teenage girls rather than boys. But, if you carefully analyze the disease, human papillomavirus, a sexually transmitted disease, its subtypes 16 and 18 not only cause approximately 70% of cervical cancers, but they cause most HPV-induced anal (95% linked to HPV), vulvar (50% linked), vaginal (65% linked), oropharyngeal (60% linked) and penile (35% linked) cancers. The viruses are generally passed through genital contact, almost always as a result of vaginal, oral and anal sex.